Yasuji Ueda

Summary

Affiliation: Taisho Pharmaceutical Co
Country: Japan

Publications

  1. ncbi request reprint A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth
    Yasuji Ueda
    Taisho Pharmaceutical Co, Ltd, 1 403 Yoshino cho, Kita ku, 331 9530 Saitama, Japan
    Cancer Chemother Pharmacol 54:16-24. 2004
  2. ncbi request reprint VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo
    Yasuji Ueda
    Taisho Pharmaceutical Co, Ltd, 1 403 Yoshino cho, Kita ku, Saitama, Japan
    Anticancer Res 24:3009-17. 2004
  3. ncbi request reprint Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155
    Yasuji Ueda
    Taisho Pharmaceutical Co, Ltd, 1 403 Yoshino cho, Kita ku, Saitama 331 9530, Japan
    Anticancer Res 25:3973-7. 2005
  4. ncbi request reprint A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155
    Yasuji Ueda
    Taisho Pharmaceutical Co, Ltd, Saitama, Japan
    Mol Cancer Ther 2:1105-11. 2003
  5. ncbi request reprint Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia
    Hideaki Amada
    Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, Saitama, Japan
    Chem Pharm Bull (Tokyo) 61:286-91. 2013
  6. doi request reprint Blocking S1P interaction with S1P₁ receptor by a novel competitive S1P₁-selective antagonist inhibits angiogenesis
    Yasuyuki Fujii
    Department of Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co Ltd, 1 403 Saitama, Saitama 331 9530, Japan
    Biochem Biophys Res Commun 419:754-60. 2012
  7. ncbi request reprint Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma cells orthotopically implanted into syngeneic mice
    Yasushi Aozuka
    Division of Pathogenic Biochemistry, Department of Bioscience, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930 0194, Japan
    Cancer Lett 216:35-42. 2004
  8. ncbi request reprint New selective amplifier genes containing c-Mpl for hematopoietic cell expansion
    Takeyuki Nagashima
    DNAVEC Research, Incorporated, 1 25 11, Kannondai, Tsukuba shi, Ibaraki ken 305 0856, Japan
    Biochem Biophys Res Commun 303:170-6. 2003
  9. ncbi request reprint In vivo expansion of gene-modified hematopoietic cells by a novel selective amplifier gene utilizing the erythropoietin receptor as a molecular switch
    Takeyuki Nagashima
    DNAVEC Research Inc, Ibaraki 305 0856, Japan
    J Gene Med 6:22-31. 2004
  10. ncbi request reprint Cytoplasmic expression and extracellular deposition of an antiangiogenic factor, pigment epithelium-derived factor, in human atherosclerotic plaques
    Hiromitsu Baba
    Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Fukuoka 812 8582, Japan
    Arterioscler Thromb Vasc Biol 25:1938-44. 2005

Collaborators

Detail Information

Publications11

  1. ncbi request reprint A novel low molecular weight VEGF receptor-binding antagonist, VGA1102, inhibits the function of VEGF and in vivo tumor growth
    Yasuji Ueda
    Taisho Pharmaceutical Co, Ltd, 1 403 Yoshino cho, Kita ku, 331 9530 Saitama, Japan
    Cancer Chemother Pharmacol 54:16-24. 2004
    ..These results suggest that VGA1102 inhibits VEGF function resulting in inhibition of tumor angiogenesis, which led to suppression of growth of human tumors transplanted into nude mice...
  2. ncbi request reprint VGA1155, a novel binding antagonist of VEGF, inhibits angiogenesis in vitro and in vivo
    Yasuji Ueda
    Taisho Pharmaceutical Co, Ltd, 1 403 Yoshino cho, Kita ku, Saitama, Japan
    Anticancer Res 24:3009-17. 2004
    ..VGA1155 thus exhibits promise as an antiangiogenic or anti-tumor agent with fewer side-effects...
  3. ncbi request reprint Antitumor effects of synthetic VEGF-receptor binding antagonist, VGA1155
    Yasuji Ueda
    Taisho Pharmaceutical Co, Ltd, 1 403 Yoshino cho, Kita ku, Saitama 331 9530, Japan
    Anticancer Res 25:3973-7. 2005
    ..These results suggest that VGA1155 has antitumor effects in vivo through the inhibition of VEGF binding to its receptors...
  4. ncbi request reprint A novel low molecular weight antagonist of vascular endothelial growth factor receptor binding: VGA1155
    Yasuji Ueda
    Taisho Pharmaceutical Co, Ltd, Saitama, Japan
    Mol Cancer Ther 2:1105-11. 2003
    ..These VGA1155 activities may provide a useful basis for the development of antiangiogenic and antitumor agents...
  5. ncbi request reprint Discovery of 7-methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): a potent and selective transforming growth factor-β type I receptor inhibitor as a topical drug for alopecia
    Hideaki Amada
    Medicinal Chemistry Laboratories, Taisho Pharmaceutical Co, Ltd, Saitama, Japan
    Chem Pharm Bull (Tokyo) 61:286-91. 2013
    ..Furthermore, the topical application of 3% 11 lotion significantly inhibited Smad2 phosphorylation in mouse skin at 8 h after application (71% inhibition, compared with vehicle-treated animals)...
  6. doi request reprint Blocking S1P interaction with S1P₁ receptor by a novel competitive S1P₁-selective antagonist inhibits angiogenesis
    Yasuyuki Fujii
    Department of Molecular Function and Pharmacology Laboratories, Taisho Pharmaceutical Co Ltd, 1 403 Saitama, Saitama 331 9530, Japan
    Biochem Biophys Res Commun 419:754-60. 2012
    ..These findings revealed that S1P(1) is a critical component of VEGF-related angiogenic responses and also provide evidence for the efficacy of TASP0277308 for anti-cancer therapies...
  7. ncbi request reprint Anti-tumor angiogenesis effect of aminopeptidase inhibitor bestatin against B16-BL6 melanoma cells orthotopically implanted into syngeneic mice
    Yasushi Aozuka
    Division of Pathogenic Biochemistry, Department of Bioscience, Institute of Natural Medicine, Toyama Medical and Pharmaceutical University, 2630 Sugitani, Toyama 930 0194, Japan
    Cancer Lett 216:35-42. 2004
    ..These findings suggest that bestatin is an active anti-angiogenic agent that may inhibit tumor angiogenesis in vivo and tube-like formation of endothelial cells in vitro through its inhibition of APN/CD13 activity...
  8. ncbi request reprint New selective amplifier genes containing c-Mpl for hematopoietic cell expansion
    Takeyuki Nagashima
    DNAVEC Research, Incorporated, 1 25 11, Kannondai, Tsukuba shi, Ibaraki ken 305 0856, Japan
    Biochem Biophys Res Commun 303:170-6. 2003
    ..The Mpl-type SAGs induced more potent proliferation of Ba/F3 and cynomolgus CD34(+) cells than the GCR-type SAG. One mutant Mpl-type SAG (Delta GCRMplTmR) successfully lost the responsiveness to TPO without affecting the Tm-dependence...
  9. ncbi request reprint In vivo expansion of gene-modified hematopoietic cells by a novel selective amplifier gene utilizing the erythropoietin receptor as a molecular switch
    Takeyuki Nagashima
    DNAVEC Research Inc, Ibaraki 305 0856, Japan
    J Gene Med 6:22-31. 2004
    ..In this study, we have developed a new-generation SAG, in which the erythropoietin (EPO) receptor (EPOR) is utilized instead of the steroid receptor as a molecular switch...
  10. ncbi request reprint Cytoplasmic expression and extracellular deposition of an antiangiogenic factor, pigment epithelium-derived factor, in human atherosclerotic plaques
    Hiromitsu Baba
    Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, 3 1 1 Maidashi, Fukuoka 812 8582, Japan
    Arterioscler Thromb Vasc Biol 25:1938-44. 2005
    ..To assess the expression and distribution of a neurotrophic/antiangiogenic factor, pigment epithelium-derived factor (PEDF), related to angiogenesis that is a possibly key event during atherogenesis in human atherosclerotic plaques...
  11. ncbi request reprint Development of immunostimulatory virotherapy using non-transmissible Sendai virus-activated dendritic cells
    Yasuo Yoneyama
    Department of Gene Therapy, Chiba University, Chiba, Japan Department of Frontier Surgery, Chiba University, Chiba, Japan
    Biochem Biophys Res Commun 355:129-35. 2007
    ..This is the first demonstration that non-transmissible SeV vector, SeV/dF, could be a DC-activator; DC/SeV/dF-based cancer immunotherapy may, therefore, warrant further investigation...